Richard Bruce Brandon
Fondatore presso Immunexpress Pty Ltd.
Profilo
Richard Bruce Brandon is the founder of Immunexpress Pty Ltd., where he currently holds the title of Chief Scientific Officer since 2013.
He is also the founder of Immunexpress, Inc., where he currently holds the title of Chief Scientific Officer since 2010.
Posizioni attive di Richard Bruce Brandon
Società | Posizione | Inizio |
---|---|---|
Immunexpress Pty Ltd.
Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Fondatore | 01/01/2006 |
Immunexpress, Inc.
Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in | Fondatore | 01/01/2010 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Immunexpress Pty Ltd.
Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Health Technology |
Immunexpress, Inc.
Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in | Commercial Services |
- Borsa valori
- Insiders
- Richard Bruce Brandon